Germline variants analysis of Chinese breast cancer patients reveals numerous alterations in homologous recombination genes
HR-gene testing in breast cancer could help to find new suspected pathogenic variants and increase the clinical benefit of multi-gene testing for breast cancer.
Authors
- Zhaoyun Jiang (ORCID: https://orcid.org/0000-0001-5441-7504)
- Bing Xu (ORCID: https://orcid.org/0000-0002-7271-4438)
- Bo Sun (ORCID: https://orcid.org/0000-0001-8166-7517)
- Beibei Yang (ORCID: https://orcid.org/0009-0001-3983-1675)
- Su Lu (ORCID: https://orcid.org/0000-0002-0311-7955)
- Mengjian Li (ORCID: https://orcid.org/0009-0000-9698-8508)
- Qixi Wu (ORCID: https://orcid.org/0000-0002-9959-2629)
- Juan Zhang (ORCID: https://orcid.org/0000-0002-3216-1162)
- Liqiang Qi
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Cancer Institute (WIA) (IN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Future Science OA
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1080/20565623.2025.2458432
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China